Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

MRNS has been the topic of several other research reports. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, Royal Bank of Canada reduced their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.31 on Wednesday. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26. The stock has a market capitalization of $17.11 million, a PE ratio of -0.13 and a beta of 1.25. The firm’s fifty day moving average price is $0.93 and its 200 day moving average price is $1.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after buying an additional 132,689 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at about $34,000. Values First Advisors Inc. lifted its holdings in Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 52,257 shares during the period. Hussman Strategic Advisors Inc. grew its position in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $813,000. 98.80% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.